The XCL1-Glypican-3 fusion gene has been developed as a cancer vaccine,15 showing promise in enhancing the generation of GPC3-specific CD8+ T cells, delaying liver cancer growth and improving the efficacy of anti-PD-1 therapy. The gene discussed is GPC3; the disease is cancer.